H.R. 8091 is a Florida House resolution that designates April 6–12, 2026 as “Vein Week” in the state. The text frames venous and lymphatic disease — especially venous thromboembolism (deep vein thrombosis and pulmonary embolism) — as a serious, under-recognized public health problem and formally endorses the international awareness initiative.
The resolution cross-references recent state actions — the 2025 Emily Adkins Family Protection Act requiring risk screening and Florida’s blood clot registry — signaling legislative alignment around prevention and data collection. The measure is ceremonial: it declares a week for awareness but includes no appropriation, regulatory requirements, or new authorities.
At a Glance
What It Does
The bill adopts a one-week, statewide designation — “Vein Week” — and records a set of findings about the health risks posed by venous and lymphatic disease. It cites international Vein Week and recent Florida statutes on screening and data collection.
Who It Affects
Directly affected parties are public health agencies, clinicians and hospital systems that run or promote VTE screening, patient-advocacy groups that organize outreach, and researchers who use the state blood clot registry. The resolution does not itself change clinical obligations or insurance rules.
Why It Matters
Although nonbinding, the resolution gives official imprimatur to screening and registry efforts already on Florida’s books, increasing the likelihood that agencies and stakeholders will use the designated week for campaigns, provider education, and data-driven outreach activities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution begins with a set of “whereas” clauses that summarize the public-health problem: venous thromboembolism (VTE) is presented as a leading cause of preventable illness and hospital death, and early detection and education can reduce harm. The preamble explicitly connects Florida to the internationally observed Vein Week in April and to the state’s own recent legislation addressing VTE.
The operative text is short and straightforward: the House declares April 6–12, 2026 to be “Vein Week” in Florida, stating the purpose as increasing awareness of venous and lymphatic disease and the value of early detection and prevention. The resolution records policy context — notably the Emily Adkins Family Protection Act (2025) and Florida’s blood clot registry — but does not direct agencies to undertake specific actions.Because the document is a House resolution, it functions as a formal expression of the chamber’s position rather than binding law.
Practically, the most likely downstream effect is message amplification: state and local health departments, provider groups, hospitals, and patient organizations can cite the designation to justify educational events, screening reminders, or data releases tied to the registry. Those activities, however, remain voluntary unless separately funded or required.Finally, the resolution reinforces legislative framing of VTE as a chronic public-health concern and reiterates ongoing policy building blocks in Florida (screening requirements and a registry).
It leaves operational choices — who runs campaigns, how screening is prioritized in clinical workflows, and whether the state allocates money — to existing agencies and stakeholders.
The Five Things You Need to Know
The resolution designates April 6–12, 2026 as “Vein Week” in Florida.
H.R. 8091 is a House resolution: it expresses the chamber’s stance but does not create binding law, impose mandates, or provide funding.
The bill’s preamble identifies venous thromboembolism (deep vein thrombosis and pulmonary embolism) as a leading cause of preventable hospital death.
The text explicitly references the Emily Adkins Family Protection Act (2025), which the resolution says requires screening for VTE risks.
The resolution notes that Florida created the first U.S. blood clot registry to collect data for advancing treatment and research.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Frames the public-health problem and links to international Vein Week
The preamble compiles findings: VTE and lymphatic disease are common, under-recognized, and preventable with education and screening. By referencing the international Vein Week initiative, the House ties the state designation to an existing awareness calendar, which helps stakeholders coordinate timing for campaigns and clinician outreach.
Acknowledges state screening requirements and the blood clot registry
Several whereas clauses cite the Emily Adkins Family Protection Act (2025) and Florida’s blood clot registry. That linkage signals legislative continuity: the resolution endorses the direction of existing state policy (screening and data collection) without changing those statutes. For administrators and clinicians, the mention serves as political backing for actions already authorized by law.
Operative declaration creating ‘Vein Week’
The single operative provision names April 6–12, 2026 as Vein Week in Florida and states the purpose of promoting awareness and early detection. Legally this is declarative; the clause imposes no duties, timelines, or reporting requirements on agencies or providers.
No appropriation, enforcement mechanism, or administrative mandate
The resolution contains no funding language, no directive to state agencies, and no enforcement mechanism. That omission matters: any public-awareness campaigns, screening rollouts, or registry reporting tied to Vein Week will require separate administrative decisions or appropriations by agencies, health systems, or private organizations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients at elevated VTE risk: the designation can increase public messaging about prevention, symptom recognition, and the importance of screening, potentially improving timely care.
- Clinicians and hospital systems: the formal recognition provides an opportunity to amplify existing screening protocols and provider education efforts under the 2025 screening law.
- State and local public health agencies: the resolution gives these agencies a calendar hook for outreach and public-information campaigns without needing new legislative authority.
- Patient advocacy groups and medical societies: the official designation strengthens advocacy asks and fundraising pitches for awareness events and can help coordinate statewide activities.
- Researchers and registry operators: the resolution’s reference to the blood clot registry raises the visibility of data-collection efforts and may encourage data-sharing initiatives or analytic projects.
Who Bears the Cost
- State public-health departments: any promotional campaigns, staff time, or materials used to mark Vein Week will likely be absorbed within existing budgets unless the legislature appropriates separate funds.
- Hospitals and clinics: if providers intensify screening or run outreach tied to Vein Week, they will face operational costs (staff time, screening processes, follow-up care) already implicated by the 2025 screening law.
- Patient advocacy organizations and medical societies: these groups may invest time and money to organize events or educational materials to capitalize on the designation.
- Registry administrators: increased public attention can create operational demands for data curation, analysis, and potentially expanded reporting, all of which require resources.
Key Issues
The Core Tension
The central tension is between symbolism and substance: the House can boost visibility for venous disease through a nonbinding designation, but visibility alone does not solve the logistical, financial, and privacy challenges of expanding screening, managing follow-up care, or scaling registry operations — and stakeholders may reasonably disagree about whether a symbolic week should trigger material commitments.
The resolution is intentionally symbolic: it aims to concentrate attention but does not allocate resources or create enforceable duties. That structure creates an implementation gap — stakeholders may expect action after a formal designation, yet any substantive campaigns or screening expansions require separate funding or administrative directives.
For entities already subject to the Emily Adkins screening requirement, Vein Week is an opportunity to publicize compliance, but the resolution itself does not clarify how screening rates, follow-up care, or registry reporting should be measured or supported.
Linking the week to both a screening mandate and the state’s blood clot registry creates a coherence benefit and a potential policy confusion. On one hand, it aligns messaging with concrete state programs; on the other, it risks implying that the resolution changes clinical standards or privacy obligations when it does not.
Increased publicity for the registry also raises practical questions about data governance, consent, and resource capacity that the resolution does not address.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.